First-generation DESs fracture more often that thought, study shows
This article was originally published in Clinica
Executive Summary
The rates of fracturing in first-generation drug-eluting stents (DESs) is "much higher than clinically reported", a trial has found.
You may also be interested in...
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.
PureTech Hopes For A Second Lightning Strike
Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?
Semaglutide Might Treat Heart Failure Directly
Novo Nordisk’s product’s reputation as a wonder drug grows as new data suggest it might be disease-modifying in heart failure.